Endocrinology: Recent Episodes
ReachMD
Guest: Andre Harvin, PharmD, MS, MBA
Biosimilars have greatly impacted the US healthcare system over the last decade, creating cost savings and increasing access for patients.1,2 However, although some biosimilars have seen significant adoption, not all biosimilars have been able to achieve sustainable market use.1 Learn about the barriers to biosimilar adoption in the US and strategies for overcoming them from Dr. Andre Harvin. Dr. Harvin is the chief pharmacy officer at Cone Health in Greensboro, North Carolina.
References:
- AAM, The U.S. Generic & Biosimilar Medicines Savings Report, September 2023
- IQVIA Institute for Human Data Science, Biosimilars in the United States 2023-2027: Competition, Savings, and Sustainability, January 2023
© Fresenius Kabi USA, LLC 2025 03/2025
Guest: Orly Vardeny, MD
Guest: Muthiah Vaduganathan, MD, MPH
Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.
Guest: Muthiah Vaduganathan, MD, MPH
Guest: Orly Vardeny, MD
Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.
Guest: Walmir Coutinho, MD
Guest: Charles P. Vega, MD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Charles P. Vega, MD
Guest: Walmir Coutinho, MD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Donna Ryan, MD
Guest: Andreea Ciudin, MD, PhD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Andreea Ciudin, MD, PhD
Guest: Marta Comas
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Donna Ryan, MD
Guest: Andreea Ciudin, MD, PhD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Donna Ryan, MD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Guest: Charles P. Vega, MD
Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.
Host: Raymond Townsend, MD
Guest: Melissa Magwire, RN, MSN, CDE
Guest: Michael Weber, MD
The outcomes of large clinical trials such as EMPA-REG have demonstrated that SGLT2 inhibitors are effective, but they do more than lower blood sugar and improve A1c. Similar to statins a long time ago, SGLT2 inhibitors offer many advantages for patients with potential atherosclerotic endpoints. Learn from our expert multidisciplinary panel as they explore the various approaches to treatment that can improve outcomes and quality of life in your patients with cardiorenal comorbidities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nadia Merchant, MD
Guest: Melody Shi, MD
Guest: Despoina Galetaki, MD
Steroids are one of the main treatments for patients with Duchenne muscular dystrophy (DMD), but prolonged steroid use can come with many endocrine side effects, like weight gain, insulin resistance, and adrenal insufficiency. To learn more about these endocrine complications and surveillance, a recent survey was conducted, and here to share the results with Dr. Charles Turck are study authors Drs. Nadia Merchant, Melody Shi, and Despoina Galetaki.
Host: Matt Birnholz, MD
Guest: Saad Kenderian M.B, Ch.B
CAR T-cell therapy has been revolutionary in the treatment of blood cancers like chronic lymphocytic leukemia and multiple myeloma, and according to recent research, this therapeutic approach may also help patients with thyroid cancer. However, there are several challenges associated with applying this technology to target solid tumors in thyroid cancer, like tumor heterogeneity and resistance. Joining Dr. Matt Birnholz to talk about these challenges and how a research team is working to overcome them is Dr. Saad J. Kenderian, Assistant Professor of Oncology, Immunology, and Medicine at the Mayo Clinic in Rochester, Minnesota.
Host: Daniel Gaudet, MD, PhD
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Marc P. Bonaca, MD, MPH
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Manesh R. Patel, MD
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Marc P. Bonaca, MD, MPH
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Manesh R. Patel, MD
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Host: Jonathan Chung, MD
Host: Seth Kligerman, MD
Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Scott Kahan, MD, MPH
Guest: Ken Fujioka, MD
Guest: Carol Wysham, MD
Embark on a transformative journey to redefine patient care for individuals with type 2 diabetes by transitioning from the conventional focus on glycemic control to a pioneering obesity-centered approach. Immerse yourself in the expertise of 3 distinguished professionals: Drs. Carol Wysham, Scott Kahan, and Ken Fujioka. These esteemed experts will guide you through the dynamic terrain of weight loss medications, including GLP-1/GIP dual receptor agonists, and provide invaluable insights to elevate and optimize patient outcomes in the realm of type 2 diabetes management.
Host: Maria Fleseriu, MD, FACE
Guest: Richard Auchus, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Maria Fleseriu, MD, FACE
Guest: Martin Reincke, MD
Designed with primary care physicians (PCPs) in mind, this continuing medical education activity focuses on efficient screening for Cushing’s syndrome by emphasizing clinical indicators and targeted tests. Tune in to discover practical tools that can help you reach an accurate diagnosis by distinguishing between physiologic and pathologic causes. Our experts also discuss when to refer for a specialist consultation. PCPs play a pivotal role in early detection and management of Cushing's syndrome, so be sure to add these skills to your armamentarium in the primary care setting.
Host: Maria Fleseriu, MD, FACE
Guest: Richard Auchus, MD
Take your endocrinology practice to the next level and gain in-depth knowledge on disease recurrence, treatment options, and patient-centered care strategies. Join us as Dr. Maria Fleseriu and Dr. Richard Auchus discuss ways to optimize outcomes for your patients with Cushing's disease.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Kevin C.J. Yuen, MD
Guest: Eliza B. Geer, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Eliza B. Geer, MD
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Eliza B. Geer, MD
Guest: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Eliza B. Geer, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Kevin C.J. Yuen, MD
Guest: Susan L Samson, MD, PhD, FRCPC, FACE
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Eliza B. Geer, MD
Guest: Kevin C.J. Yuen, MD
Elevate your clinical expertise in acromegaly by delving into the latest advances in diagnosis, treatment modalities, and patient-centered care to foster a deeper understanding of optimal management strategies. Join us to enhance your skills and contribute to improved outcomes for patients with acromegaly.
Host: Maria Fleseriu, MD, FACE
Guest: Martin Reincke, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Martin Reincke, MD
Guest: Maria Fleseriu, MD, FACE
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Martin Reincke, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Maria Fleseriu, MD, FACE
Guest: Martin Reincke, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Richard Auchus, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Maria Fleseriu, MD, FACE
Guest: Richard Auchus, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: Maria Fleseriu, MD, FACE
Guest: Richard Auchus, MD
Tune in to this continuing education activity on Cushing's Disease to enhance your knowledge of strategic screening methods to identify high-risk individuals. Our experts emphasize the importance of using advanced diagnostic tools to achieve an accurate and early diagnosis. Their discussion delves into the latest treatment modalities, ensuring participants are well versed in timely and tailored therapeutic approaches for optimal patient care. Add these comprehensive insights to your clinical practice armamentarium and keep up with the evolving landscape of Cushing's disease management.
Host: George L. Bakris, MD, FAHA, FASN
Guest: David Bushinsky, MD
Guest: Lars Lund, MD
Hyperkalemia is a limiting factor when treating patients with heart failure and CKD on RAASi therapy. It’s especially challenging when these patients are on chronic hemodialysis. Join Drs. George Bakris, David Bushinsky, and Lars Lund as they identify the barriers of optimal treatment in patients on hemodialysis and discuss the real-world evidence using potassium-lowering agents in challenging patient group.
Guest: David E. Bernstein, MD, MACG, FAASLD
Guest: Steven Flamm, MD, FAASLD, FACG
Join us as expert faculty, Dr. Steven Flamm and Dr. David Bernstein, take us through the clinical care pathway to help PCPs recognize patients with risk factors for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). This 15-minute activity incorporates elements of role-play, reflection, and learning from one’s mistakes to improve the competence of PCPs in recognizing risk factors for NAFLD/NASH in their patients and taking the best next steps for their care.
Host: Ellie Kelepouris, MD, FACP, FAHA
Guest: Stephen J. Greene, MD, FACC, FHFSA
Patients with heart failure and chronic kidney disease (CKD) are challenging to manage. The best approach is a multidisciplinary one, which will help to optimize guideline-directed medical therapy in patients at risk for hyperkalemia. Join Drs. Ellie Kelepouris and Stephen Greene as they discuss how to identify patients at high risk of developing hyperkalemia and the available treatment strategies for these complex patients.
Host: John Buse, MD, PhD
Guest: Elizabeth Selvin, PhD, MPH
As obesity rates continue to rise in adults with type 1 diabetes, what can we do to combat this growing obstacle? Dr. John Buse speaks with an expert in the field, Dr. Elizabeth Selvin, about obesity in patients with type 1 diabetes and shares management strategies.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Scott D. Isaacs, MD FACP, FACE
Since type 2 diabetes is the number one risk factor for the progression to advanced liver fibrosis, monitoring diabetic patients is absolutely critical, especially considering the fact that the symptoms of disease progression can be nonexistent or very vague. Here with Dr. Mary Katherine Cheeley to break down the latest guidelines and strategies for monitoring liver health in patients with diabetes is endocrinologist Dr. Scott D. Isaacs.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jamy Ard, MD
Guest: Michelle I. Cardel, PhD, MS, RD
Addressing obesity may be a key component of diabetes management, so integrating strategies to manage obesity may improve diabetes care. To better understand this, Dr. Jamy Ard and Dr. Michelle Cardel dive into the impact of evidence-based lifestyle interventions for people living with diabetes.
WW Logo and Weight Watchers are the trademarks of
WW International, Inc. and are used with permission.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Kevin C. Maki, PhD, FNLA, CLS
At the American College of Cardiology's 72nd Annual Scientific Session & Expo, cardiologists will gather to explore the latest advancements in the field. Joining us to share what you can expect to learn about statin intolerance at their upcoming session are Dr. Mary Katherine Cheeley and Dr. Kevin Maki.
Host: John Buse, MD, PhD
Guest: Sue Pedersen, MD, FRCPC
New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD
Guest: Scott D. Isaacs, MD FACP, FACE
Recently, the American Association of Clinical Endocrinology and the American Association for the Study of Liver Diseases released guideline updates on nonalcoholic steatohepatitis (NASH). How will these updates impact clinical practice? Drs. Zobair M.Younossi and Scott D. Isaacs join Dr. Charles Turck to share their insights on these updated guidelines.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Michael Donovan, PhD, MD
Diabetic kidney disease (DKD) can be burdensome for patients—especially if it progresses. How can we find out if our patients are at risk of progression? To answer that question, Dr. Charles Turck is joined by Dr. Michael Donovan to discuss a prognostic tool for type 2 diabetes patients with early-stage (stage 1-3b) chronic kidney disease.
Host: Ira M. Jacobson, MD
Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD
Guest: Aaron Z. Tokayer, MD
The use of noninvasive tools in NAFLD/NASH has become more prevalent over the last several years, with increased availability of imaging and serum-based tools. A forum of experts convened to discuss optimal use of these tools in NAFLD/NASH using a series of clinical assertion statements. These statements covered screening patients with diabetes, applicability of liver enzymes in determining fibrosis stage, use of transient elastography and blood-based tools, such as the Enhanced Liver Fibrosis test, and potential genetic testing. Here, Drs Jacobson and Younossi summarize the research and discussion points from the forum.
Host: Jennifer Caudle, DO
Guest: Joseph Aloi, MD
The rate of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) continues to rise. What can we do to slow this progression of CKD? Dr. Joseph Aloi from the Wake Forest School of Medicine explores this growing epidemic and discusses how a new tool may aid in early risk assessment of early stage 1-3b CKD.
Host: Maria Fleseriu, MD, FACE
Guest: Irina Bancos, MD
Cushing’s disease is complex, and individualized approaches require the consideration of many patient factors. You and your patient also need to know what to expect in terms of therapeutic response and speed of recovery. Tune in as Drs. Maria Fleseriu and Irina Bancos address these challenges and more!
Host: Maria Fleseriu, MD, FACE
Guest: Irina Bancos, MD
Cushing’s disease is complex, and individualized approaches require the consideration of many patient factors. You and your patient also need to know what to expect in terms of therapeutic response and speed of recovery. Tune in as Drs. Maria Fleseriu and Irina Bancos address these challenges and more!
Host: Pam R. Taub, MD, FACC, FASPC
Guest: George L. Bakris, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: George L. Bakris, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Yehuda Handelsman, MD
The National Lipid Association (NLA) and the American College of Cardiology (ACC) recently provided recommendations to help us achieve optimal low-density lipoprotein (LDL) levels in statin-intolerant patients, but what other management strategies are available? Joining Dr. Charles Turck to answer this question and to give more key insights is Dr. Yehuda Handelsman, Medical Director and Principal Investigator at the Metabolic Institute of America.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
There are now multiple medical therapies available to facilitate weight loss in patients with type 2 diabetes (T2D). Learn who is the right patient, when these therapies should be started, and the right combinations and intensification strategies to sustain meaningful weight loss that can lower the risk of complications.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
There are now multiple medical therapies available to facilitate weight loss in patients with type 2 diabetes (T2D). Learn who is the right patient, when these therapies should be started, and the right combinations and intensification strategies to sustain meaningful weight loss that can lower the risk of complications.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
Dropping 15% or more of body weight has a greater disease-modifying effect than any other glucose-lowering intervention. Join Drs. Donna Ryan and Juan Pablo Frias as they discuss implementing an upstream intervention to weight loss and newer drugs (GIP agonists, GLP-1 receptor agonists, SGLT2 inhibitors) to help your patients experience improved effects earlier and for a longer duration. Tune in to find out how the novel dual GIP and GLP-1 receptor antagonist tirzepatide could fit into your therapeutic strategies.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
Dropping 15% or more of body weight has a greater disease-modifying effect than any other glucose-lowering intervention. Join Drs. Donna Ryan and Juan Pablo Frias as they discuss implementing an upstream intervention to weight loss and newer drugs (GIP agonists, GLP-1 receptor agonists, SGLT2 inhibitors) to help your patients experience improved effects earlier and for a longer duration. Tune in to find out how the novel dual GIP and GLP-1 receptor antagonist tirzepatide could fit into your therapeutic strategies.
Host: Charles P. Vega, MD
Guest: Rajeev Raghavan, MD, M.Ed, FASN
Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating while considering the burdens of the disease, advances in our understanding of the pathophysiology of the disease, ways to fill the unmet needs of treatment with ESAs, and the status of potential new therapies. Tune in to keep up!
Host: Charles P. Vega, MD
Guest: Rajeev Raghavan, MD, M.Ed, FASN
Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating while considering the burdens of the disease, advances in our understanding of the pathophysiology of the disease, ways to fill the unmet needs of treatment with ESAs, and the status of potential new therapies. Tune in to keep up!
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Javier Morales, MD, FACP, FACE
Out of the 32 million patients with diabetes in the United States, 40 percent also have chronic kidney disease. But what’s even more alarming is that only 10 percent of these patients know they have chronic kidney disease. So what strategies can we use to address the unmet needs and barriers faced when managing patients with chronic kidney disease and type 2 diabetes? Joining Dr. Charles Turck to answer this and other key questions is Dr. Javier Morales, Associate Clinical Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell on Long Island.
Guest: Mikhail Kosiborod, MD
Patients with diabetes-related chronic kidney disease (CKD) are at high risk for a number of adverse events over a relatively short period of time. So what do we have in terms of efficacious therapies that can help make a positive impact in that regard? Here to share what we need to know about non-steroidal mineralocorticoid receptor antagonists (MRAs) for the treatment of diabetes-related CKD is Dr. Mikhail Kosiborod, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute.
Guest: Gates B. Colbert, MD, FASN
Approximately 34 million patients live with diabetes in the United States, and up to 40 percent of those patients also have chronic kidney disease (CKD). That’s why it’s so important to know how to identify and prevent CKD progression in patients with diabetes, and here to share key strategies is Dr. Gates Colbert, Assistant Clinical Professor at Texas A&M College of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kenneth Cusi, MD, FACP, FACE
Not only is nonalcoholic steatohepatitis (NASH) the most common chronic liver condition worldwide, but it’s also becoming the number one cause of liver transplantation beyond hepatitis C. And with its growing prevalence and burden having no end in sight, Dr. Charles Turck speaks with Dr. Kenneth Cusi about how we can better recognize the symptoms of NASH in high-risk patient groups.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Nanette F. Santoro, MD
Tune out the noise and get to the heart of managing menopause and associated vasomotor symptoms. This program provides highlights from the 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Join Drs. Nanette Santoro and Lee Shulman as they dive into the latest research, which could alter your current practice patterns and help your patients cool off.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A pragmatic approach that addresses residual cardiovascular (CV) risk across a variety of risk factors and that goes beyond LDL-C lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients require review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Carol Wysham, MD
Guest: Jane J. Kim, M.D.
Since 2020, pediatricians have seen a rapid rise in new-onset type 1 diabetes in children. Is this due to the COVID-19 pandemic or an indirect consequence of it? To answer this question, Dr. Jane Kim, a pediatric endocrinologist at Rady Children's Hospital in San Diego, shares what kind of correlation she's seeing.
Host: Carol Wysham, MD
Guest: Jane J. Kim, M.D.
Emerging research details a rapid rise in type 1 diabetes in children amid the COVID-19 pandemic. But what's causing this to happen? To dive into why, Dr. Carol Wysham is joined by Dr. Jane Kim from the Rady Children's Hospital in San Diego.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Alexis McKee, MD
What communication strategies can we use to create personalized treatment plans and improve adherence among our patients with type 2 diabetes? That’s the exact question Dr. Charles Turck discusses with Dr. Alexis McKee, an Assistant Professor of Medicine in the Division of Endocrinology, Metabolism, and Lipid Research at the Washington University School of Medicine in St. Louis.
Guest: Claresa Levetan, MD
Diabetes impacts around 40 million Americans and 25% of them don't even know they have it. Luckily, Diabetes Alert Day was created to spread awareness of this widespread disease. To help us understand this campaign, Dr. Claresa Levetan, an endocrinologist at Grand View Health in Lansdale, Pennsylvania, shares insights on the importance of Diabetes Alert Day.
Host: Ruth S. Weinstock, MD, PhD
Guest: Susan B. Bressler, MD
Guest: Mark Dunbar, OD, FAAO
With the increasing prevalence of diabetes in the United States, more individuals are at risk of losing their vision due to diabetic retinopathy every day. Fortunately, research is improving our understanding of this disease. But what does the latest information mean for our patients?
Hear Dr. Susan Bressler, Dr. Mark Dunbar, and Dr. Ruth Weinstock share their perspectives as multidisciplinary specialists treating these patients. Find out what the evidence shows and how timely referral, early diagnosis, and appropriate treatment can prevent the vision-threatening complications of diabetes.
Host: Eugene E. Wright, Jr., MD
Guest: Jolanta Małyszko, MD, PhD
Guest: María José Soler, MD, PhD
Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.
Host: Rahul N. Khurana, MD
Guest: Jennifer K. Sun, MD, MPH
The results from the Protocol W and PANORAMA clinical trials have sparked a lot of talk in the retina community about what the data really mean. So how should physicians interpret these data, and what is changing for their patients with diabetic retinopathy?
Find out in this activity as Dr. Rahul Khurana and Dr. Jennifer Sun review the findings from both trials and discuss if treatment with anti-VEGF really improves outcomes for patients with moderate to severe NPDR.
Host: Carol Wysham, MD
Guest: Deepak Vashishth, PhD
Guest: Bowen Wang
Can we predict when a patient with COVID-19 requires hospitalization? To answer this question, Dr. Carol Wysham is joined by Dr. Deepak Vashishth and Mr. Bowen Wang from the Rensselaer Polytechnic Institute to share data from their study on the impact of glycemic levels and common medications on COVID-19 severity in patients with type 2 diabetes.
Host: Jacob Sands, MD
Guest: Yasmin Jayasinghe, FRANZCOG, PhD
Pediatric and adolescent oncofertility patients are cared for differently than adult patients. That’s why Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital, is here to give us an overview of the available procedures for pediatric patients and the key considerations that go along with them.
Host: Peter Rossing, DMSc, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Matthew R. Weir, MD
Achieving optimal outcomes in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remains a challenge, and treating physicians need to embrace multidisciplinary components when managing progression to CKD.
In this discussion, Drs. Gerasimos Filippatos, Peter Rossing, and Matthew Weir review the unmet needs of patients with CKD and T2D. They also explore the role of mineralocorticoid receptor antagonists (MRAs) in the treatment spectrum and review recent findings from clinical trials. Tune in to ensure you’re doing all you can for each of your patients.
Host: Jayanth Sridhar, MD
Guest: Avni P. Finn, MD, MBA
Are you aware of the latest data that adds to our understanding of the management of diabetic retinopathy (DR)? Listen in as Dr. Avni Finn and Dr. Jay Sridhar discuss what those data are and the impact they have on the early referral and timely treatment of patients with DR. Make sure you’re properly using all of the resources in your armamentarium to save your patients’ sight.
Host: Hyunseok “Hyu” Kang, MD, MPH
Guest: Jochen Lorch, MD
Although multi-kinase inhibitors (MKIs) have been the standard of care for the treatment of thyroid cancer, they produce excessive “off-target” clinical adverse effects and toxicity that limit their use in some patients, leading to drug discontinuation or dose reduction. The introduction of RET inhibitors into the thyroid cancer treatment landscape offers novel, efficacious therapies for patients who previously had limited treatment options.
This online, on-demand educational activity will review RET alterations in thyroid cancer, molecular diagnostic testing, and recent and emerging clinical data on novel therapies targeting RET-altered or RET-driven thyroid cancer. A Virtual Case Clinic Video Exercise will highlight and demonstrate the translation of these RET-targeted therapies into real-world clinical practice for the treatment of patients with thyroid cancer.
Host: Diana Shechtman, OD, FAAO
Guest: Carolyn E. Majcher, OD, FAAO
When it comes to diabetic retinopathy, studies and new data are constantly being published. Are you up to date with the progress being made? Join Dr. Diana Shechtman and Dr. Carolyn Majcher for a discussion on the latest data around the treatment of nonproliferative diabetic retinopathy and how these advances affect the management of your patients.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Eliza B. Geer, MD
The primary goals in the medical management of Cushing’s disease are to normalize cortisol levels and reduce or eliminate the associated comorbidities, physical features, and symptoms for our patients. With recently approved therapies and more in development, it really is an exciting time in this treatment space! Tune in to hear Dr. Eliza Geer discuss novel medical options and how we should remember the importance of looking at patient outcomes to make sure we’re addressing Cushing’s disease holistically.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Jacob Sands, MD
Guest: Suneeta Senapati, MD, MSCE
Guest: Mindy Christianson, MD
Patients undergoing treatments such as chemotherapy may be at significant risk of impairment or inability to have children later in life. This risk impacts both men and women equally, but fortunately, the field of oncofertility can help guide patients as they navigate their fertility options prior to cancer treatment. Here to share their insights on this emerging field with Dr. Jacob Sands are Dr. Mindy Christianson and Dr. Suneeta Senapati.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Robert J. Chilton, DO
Guest: John R. Nelson, MD, FACC, FNLA, FASNC
Join Drs. Chilton and Nelson as they discuss recent omega-3 fatty acid (OM-3) outcomes trial results and how to apply those results along with evidence-based guidelines to reduce ASCVD risk. Tune in to hear about the use of OM-3s including dietary supplement OM-3s that are readily available in pharmacies and online, so you can keep your patients informed!
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Emily Louise Johnson, MD
According to recent estimates, between 150,000 and 450,000 transgender patients have epilepsy. And as that number is only expected to grow, Assistant Professor of Neurology at Johns Hopkins School of Medicine Dr. Emily Johnson shares key considerations for treating transgender patients with epilepsy.
Host: John E. Anderson, MD
Guest: Michael Greenberg, MD
Dr. John Anderson joins Dr. Michael Greenberg, host of DermConsult, to discuss skin diseases that dermatologists should be aware of in patients with diabetes.
Guest: Carol Wysham, MD
ReachMD host Dr. Carol Wysham discusses what we currently know about hypoglycemia and cardiovascular disease, how to identify patients at risk for severe hypoglycemia, and the strategies and approaches to mitigate risk of hypoglycemia.
Guest: David M. Simpson, MD
Guest: Jon T. Gertken, MD
Guest: Stephanie Simon, NP
Find the full Prescribing Information here.
There are multiple ways to incorporate the use of Qutenza, a topical treatment for painful diabetic peripheral neuropathy of the feet, into practice. Tune in to hear Dr. David M. Simpson, Dr. Jon T. Gertken, and Ms. Stephanie Simon share their best practices for administering Qutenza as well as the management of painful diabetic peripheral neuropathy of the feet.
QUTENZA® is a registered trademark of Averitas Pharma, Inc.
© 2021 Averitas Pharma, Inc. All rights reserved.
M-QZA-US-01-21-0065 June 2021
Guest: Kevan C. Herold, MD
Guest: Andrea Steck, MD
Guest: Anette Gabriele Ziegler, MD
Experts in the immunopathology of type 1 diabetes review data showing that clinical presentation is preceded by an asymptomatic phase, characterized by the presence of one or more islet autoantibodies. Screening children for islet autoantibodies during the two preclinical stages can identify those with multiple autoantibodies and high-risk antibody phenotypes who may be candidates for preventive interventions before developing dysglycemia or the clinical onset of type 1 diabetes.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Alexis McKee, MD
Since patients with type 2 diabetes on multiple daily injections of insulin are at high risk of hypoglycemia, Dr. Charles Turck discusses essential counseling strategies for these high-risk patients with Dr. Alexis Mckee, an endocrinologist and Assistant Professor of Medicine at Washington School of Medicine in St. Louis, Missouri. Together, they’ll review how we can help patients avoid, manage, and treat hypoglycemia emergencies.
Guest: Brett Nowlan, MD
Metabolic dysfunction is the central driver for conditions with some of the highest mortality rates. Identifying this dysfunction early on is essential to preventing disease progression. Dr. Brett Nowlan, a cardiologist at Cottage Grove Cardiology in West Hartford, Connecticut, explains why.
Guest: Christie M. Ballantyne, MD
Host: John J. Russell, MD
According to the Consensus Statement published by the European Atherosclerosis Society, more than 90% (and maybe as high as 99%) of individuals with FH in the US have not been properly diagnosed due to gaps in screening, recognition and classification of FH. If not identified and aggressively treated from an early age, individuals with FH have a 20-fold increased life time risk of heart disease compared to the general population. However, with optimal treatment, an affected individual’s lifetime risk of cardiovascular disease approaches the risk found in the general population. Although the clinical symptoms are not as pronounced in cases of heterozygous FH, both homozygous (HoFH) and heterozygous FH (HeFH) patients still have an elevated risk of developing coronary heart disease at some point in their life. Early diagnosis and treatment for both HoFH and HeFH can significantly reduce the risk of coronary heart disease or delay its onset. Both homozygous and heterozygous FH are serious conditions that require special attention and treatment.
Host: Michael Miller, MD, FACC, FAHA, FNLA
Guest: Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC
In 2019, the REDUCE-IT trial studying eicosapentaenoic acid (EPA), a purified form of omega-3 fatty acid, was published and demonstrated a dramatic 25% reduction in major cardiovascular events. In 2020, the STRENGTH trial that used a carboxylic acid formulation of combined EPA and docosahexaenoic acid (DHA), was surprisingly neutral and the study was halted for futility. A recent post hoc analysis of the STRENGTH study failed to show a difference in the primary endpoint in the highest tertile group receiving the EPA/DHA carboxylic acid treatment. Why did these two major omega-3 clinical trials studying patients with elevated triglyceride levels have disparate results? What does this mean for our patients? Join two experts, Drs. Michael Miller and Brian Olshansky, as they assess the different trials and offer their perspective on the clinical and scientific implications of the results.
Guest: Kevan C. Herold, MD
Guest: Stephen Gitelman, MD
Experts in the immunopathology of type 1 diabetes consider the potential role of monoclonal antibodies, disease modifying agents, and other agents to prevent or delay the onset of clinical disease. Particular emphasis will be placed on the CD3 cell surface marker and anti-CD3 monoclonal antibodies, which has been shown to slow progression to clinical type 1 diabetes in high risk persons.
Host: Vivian Fonseca, MD, FRCP
Guest: Rishi P. Singh, MD
Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Acromegaly is a rare disorder caused by excess growth hormone production and is associated with increased morbidity and mortality. Delays in the diagnosis and initiation of therapy or the provision of suboptimal therapy often negatively impact the quality of life of these patients. Join us for this expert interview with Dr. Susan Samson and Dr. Kevin Yuen who offer insights to help you overcome the complex medical challenges often faced when managing patients with acromegaly, including strategies to apply the latest guidelines and the 2020 consensus statement into clinical practice.
Host: John E. Anderson, MD
Guest: Raghu Mirmira, MD,PhD
When treating type 1 diabetes, should we be focusing on disease prevention rather than reversal? Dr. John Anderson takes a look at prevention tactics for type 1 diabetes progression with Dr. Raghu Mirmira, a Professor of Medicine and the Director of the Translational Research Center at the University of Chicago.
Guest: Kevan C. Herold, MD
Guest: Chantal Mathieu, MD, PhD
Experts in the immunopathology of type 1 diabetes discuss the epidemiology, non-genetic and genetic risk factors, and progression from preclinical to clinical stages of this disease. The discussion will emphasize the breakdown of immune tolerance that precedes type 1 diabetes and the subsequent pathogenetic role of islet autoantibodies responsible for its clinical manifestations.
Host: John Buse, MD, PhD
Guest: Anne Louise Peters, MD
SGLT-2 inhibitors have been authorized for diabetic patients in Europe, but is it close to receiving FDA approval in the U.S.? Dr. Anne Peters of USC speaks with Dr. John Buse about SGLT-2 inhibitors and considerations for diabetic ketoacidosis, heart failure, and chronic kidney disease.
Host: Hector O. Chapa, MD, FACOG
Guest: Andrew Little, DO
When vascular access is compromised, intraosseous access, or IO access, can help prevent fatal consequences. What do we need to know about implementing and managing this type of device? Dr. Hector Chapa is joined by Dr. Andy Little, the Associate Program Director for AdventHealth Orlando Emergency Medicine Residency, to share some insight on IO vascular access.
Host: John Buse, MD, PhD
Guest: Antonios Douros, MD
Dr. John Buse joins Dr. Antonios Douros, Assistant Professor in the Department of Medicine at McGill University and research investigator at Lady Davis Institute in Montreal, Quebec, to discuss his latest research focusing on SGLT2 inhibitors and diabetic ketoacidosis risk.
Host: Carol Wysham, MD
Guest: Alexis McKee, MD
Patient care has evolved amid the COVID-19 pandemic, causing unexpected challenges in managing diseases such as diabetes. Dr. Carol Wysham joins Dr. Alexis McKee, a practicing endocrinologist and an assistant professor of medicine at Washington School of Medicine in St. Louis, Missouri, to discuss how patients have been overcoming challenges in managing diabetes during the pandemic.
Host: John Buse, MD, PhD
Guest: David Wheeler, MB, CHB, MD, FRCP
Recent research has revealed that a type 2 diabetes treatment may help manage chronic kidney disease. Dr. John Buse discusses the use of dapagliflozin in patients with chronic kidney disease with Dr. David Wheeler, a professor of kidney medicine at the University College London in the United Kingdom, and an honorary consultant nephrologist at the Royal Free London NHS Foundation Trust.
Host: Carol Wysham, MD
Guest: Janet B. McGill, MD, MA, FACE, FACP
Many patients with diabetes don’t fit into our stereotypes of type 1 or type 2 diabetes and identifying them is key to understanding how to treat them. Dr. Carol Wysham discusses atypical diabetes with Dr. Janet McGill, a professor of medicine at the Washington School of Medicine in St. Louis, Missouri.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joshua Stolker, MD
Patients with type 2 diabetes face a higher risk of cardiovascular morbidity and mortality than adults without diabetes. How does this understanding specifically affect the way cardiologists manage their patients with type 2 diabetes? Joining Dr. Charles Turck to explore recently updated recommendations and their impacts on cardiology practice is interventional cardiologist Dr. Joshua Stolker.
To view the 2020 American College of Cardiology Expert Consensus Decision Pathway click here.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US20DI00435 February 2021
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Alan S. Brown, MD, FACC, FAHA, FNLA
With an explosion in new medications to treat diabetes, Heart Matters hosts Dr. Matthew Sorrentino and Dr. Alan Brown sit down to discuss the cardiovascular risk benefits of these new diabetes treatments and how cardiologists can improve patient care.
Guest: Joshua Stolker, MD
The 2020 American College of Cardiology Expert Consensus Decision Pathway provides a change in mindset for the cardiology field when it comes to treating patients with type 2 diabetes with established cardiovascular disease. Here to walk us through these updated recommendations is Dr. Joshua Stolker, an interventional cardiologist at Mercy Clinic Heart and Vascular in Saint Louis, Missouri.
To view the 2020 American College of Cardiology Expert Consensus Decision Pathway click here.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US20DI00430 January 2021
Host: John E. Anderson, MD
Guest: Jason Sloane, MD
There’s no denying that the COVID-19 pandemic has impacted every aspect of healthcare. So in an effort to recognize those who’ve gone above and beyond the call of duty, ReachMD’s Heroes in Healthcare initiative honors those healthcare professionals who were nominated by their peers for their outstanding contributions to the field of medicine. And one such nominee, Dr. Jason Sloane, joins Dr. John Anderson to discuss this nomination, strategies for optimal care, and his response to the COVID-19 pandemic.
Guest: Pablo F. Mora, MD
The glycemic control algorithm that’s part of the American College of Endocrinology Consensus Statement for 2020 is separated into several parts, and here to break them down for us is Dr. Pablo Mora, Clinical Professor with the Division of Endocrinology at the University of Texas Western Medical Center of Dallas.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US20DI00336 October 2020
Host: Jennifer Caudle, DO
Guest: Lisa A. Coco, CRNP
Guest: Deborah Hinnen, APN, BC-ADM, CDCES, FAAN
Guest: Davida F. Kruger, CNP
When a patient with diabetes has cardiovascular disease, they’re at greater risk for morbidity and mortality. That’s why the American Diabetes Association’s 2020 Standards of Medical Care in Diabetes aim to address this and other health risks, and here to walk us through this new treatment algorithm are nurse practitioners Lisa Coco, Debbie Hinnen, and Davida Kruger.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US20DI00343 October 2020
Host: Shira Johnson, MD
Guest: Sabrina E. Noel, PhD, RD
While osteoporosis was thought to have affected primarily non-Hispanic white women, recent evidence suggests that Hispanic men and women have a similar or higher frequency of this chronic condition. Dr. Sabrina E. Noel, Ph.D., R.D., discusses her studies regarding the prevalence of osteoporosis in the Hispanic community.
Host: Shira Johnson, MD
Guest: Andrea J. Singer, MD, FACP, CCD
While osteoporosis-related bone fractures affect nearly 54 million adults in the U.S., there’s a lot we don’t know about this bone disease. With that in mind, Dr. Andrea Singer joins us today to review a recent report from the National Osteoporosis Foundation and discuss the impact of osteoporosis on economic drivers, patient quality of life, and the healthcare system as a whole.
Guest: Lauren K. Brooks, MD
During this unprecedented time, finding the best approach to providing treatment for patients with thyroid cancer can be a challenge. Endocrinologist Dr. Lauren Brooks of Penn Medicine Lancaster General Health shares some of her approaches to this dilemma and stresses the importance of keeping up on routine practices during the COVID-19 pandemic.
Published September 28, 2020
Host: Paul Doghramji, MD
Guest: Maria Escolar, MD, MS
Adrenoleukodystrophy (ALD) is a rare genetic disorder that when left untreated, can have severe and even fatal consequences. Here to review the available treatment options for these patients is Dr. Maria Escolar, the Director of the Program for the Study of Neurodevelopment in Rare Disorders and a Professor of Pediatrics at the University of Pittsburgh School of Medicine.
Host: Mimi Secor, DNP, FNP-BC, FAANP
Guest: Felicia Cosman, MD
Here to bring to light highly sited articles over the past decade from the leading journal in osteoporosis that address the way we approach patients living with osteoporosis and the different treatment options we can use to help them is Dr. Felicia Cosman, Coeditor in Chief of the Osteoporosis International journal and Professor of Clinical Medicine at Columbia University Medical Center in New York.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Paul Orchard, MD
Although it only affects about one in 18,000 people, the impacts of adrenoleukodystrophy cannot be underestimated. That’s why Dr. Paul Orchard joins Mario Nacinovich to talk about this rare—and fatal—genetic disease, why it’s often underdiagnosed and confused with other conditions, and how we can treat it once we’ve reached an accurate diagnosis.
Host: Barnett Mennen, MD
Guest: Sarah Hallberg, MD
Carbohydrates are our main source of energy and provide important nutrients for good health. However, they are also the main culprit behind elevated blood sugar and are problematic for diabetic patients trying to control their blood sugar levels.
Host Dr. Barry Mennen sits down with Dr. Sarah Hallberg to talk about carbohydrate restriction as a key to successful weight loss programs. She prescribes that adherence to a low-carb, high-fat diet is vital to patients for controlling their diabetes, with the possibility of being able to come off medications over time.
Dr. Sarah Hallberg is the Medical Director at Virta Health and Founder of the Indiana University-Arnett Health Medical Weight Loss Program in Lafayette, Indiana.
Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk.
Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.
Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch.
A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at druginfo@fda.hhs.gov.
Released 5/16/2017
Host: Brian P. McDonough, MD, FAAFP
Polycystic Ovary Syndrom (PCOS) afflicts 10 to 15% of women worldwide, yet physicians often don't recognize the symptoms associated with this disease.
Host Dr. Brian McDonough chats with Dr. Fiona McCulloch, a Toronto-based naturopath and author of the book 8 Steps to Reverse Your PCOS, about different approaches to managing PCOS and how dietary changes can make huge impacts for women dealing with PCOS.
Host: Kathy King, RDN
Joining Kathy King to talk about vitamin D at the molecular, physiological, and clinical levels is Susan Allen, certified clinical nutritionist and owner of Next Level Functional Nutrition based in Tampa, FL.
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG
Many menopausal and perimenopausal women are faced with the decision of whether synthetic or bioidentical hormone therapy is the best option for them. There are many pros and cons for each, but questions surface from patients and clinicians alike on comparative safety and efficacy profiles.
Host Dr. Renee Allen welcomes Dr. Jocelyn Slaughter-Moore, a board-certified practicing OB/GYN at Heras Healthcare for Women. They talk about the differences between bioidentical and synthetic hormones, and whether bioidentical hormone therapy is a safe option for women.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Joyce Ross
Host Dr. Alan Brown welcomes Joyce Ross, nurse practitioner and President of the National Lipid Association. Joyce is a consultative education specialist in Cardiovascular Risk Intervention with the University of Pennsylvania Health System. She is the first Nurse Practitioner elected as President of the NLA.
Ms. Ross introduces her goals for the upcoming year, including novel efforts on behalf of the NLA to help combat America's obesity epidemic.
Host: Jennifer Caudle, DO
Host Jennifer Caudel, DO welcomes Jay Shubrook, DO, Director of Clinical Research and Diabetes Services at Touro University-California College of Osteopathic Medicine. Recorded on site at the American Osteopathic Association's annual medical education conference, Dr. Shubrook discusses a pilot study in which newly diagnosed type 2 diabetes patients were treated with early insulin rather than lifestyle changes and oral therapies alone. The results suggested not only good safety profiles, but also better long-term outcomes for patients.
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough welcomes Dr. Marcy Lake, faculty member of the Kaiser Permanente Family Medicine Residency Program in Portland Oregon and author of a recent article in American Family Physician devoted to disorders of the pituitary gland. Their discussion tours diagnostic considerations toward the workup of pituitary diseases, and emerging treatment paradigms for clinicians at general, endocrinology, and surgical levels of care.
Host: John J. Russell, MD
Guest: Candis Morello, PharmD, CDE
Candis M Morello, Professor of Clinical Pharmacy at UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, joins Dr. John Russell to talk about team-based care integrations of certified diabetes educators to help empower diabetes patients and improve long-term outcomes.
Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only.
Brought to you by
Host: John J. Russell, MD
Guest: Candis Morello, PharmD, CDE
Host Dr. John Russell welcomes Candis M. Morello, PharmD., CDE, FCSHP, Professor of Clinical Pharmacy and Associate Dean for Student Affairs at the Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Morello explains the importance of patient education, communication, and motivation needed to instill a positive and healthy approach to diabetes care.
Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only.
Brought to you by
Host: John J. Russell, MD
Guest: Neil Skolnik, MD
For clinicians managing patients with T2DM, the clinical landscape for standards of care, diagnostic methods and techniques, and treatment options has become increasingly complex. Yet despite this challenge in keeping up to date with the latest recommendations, updated practice guidelines have also made it a point to emphasize "big picture" elements in diabetes care, reinforcing mainstays of treatment that can potentially get overlooked.
On this episode, Dr. John Russell welcomes diabetes expert Dr Neil Skolnik, Associate Director of Family Medicine at Abington Jefferson Health, to explore the "Back to Basics" model in diabetes management, with emphasis on individualized therapeutic approaches and lifestyle modification strategies for improving long-term patient outcomes.
Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only.
Brought to you by
Host: Linda Bernstein, Pharm.D.
In this edition of The Pharmacy Report®, host Dr. Linda Bernstein spotlights type 1 diabetes and the new paradigms of research in disease detection, prevention and treatment. In the Movers and Shakers segment, Dr. Stephen E. Gitelman, M.D., Professor of Clinical Pediatrics and Chair of Pediatric Diabetes and Clinical Research at the University of California, San Francisco shares his fascinating path of discovery and research into this complex disease and how someday it could revolutionize therapeutic approaches for not just the patient, but at-risk family members as well.
References mentioned in this segment:
- Diabetes Center, University of California, San Francisco
- Centers for Disease Control and Prevention's 2013 Tips From Former Smokers campaign, including 1-800-QUIT NOW, a number that links callers to their state quitlines. The website is www.cdc.gov/tips and features information on the campaign, as well as information on how to quit smoking from the National Cancer Institute's www.smokefree.gov
Host: The Endocrine Society
Highlights from ENDO, the 95th Annual Meeting of The Endocrine Society. The Endocrine Society is the world's oldest, largest, and most active organization devoted to research on hormones and the clinical practice of endocrinology. Download the program to hear global thought leaders discuss the newest and exciting presentation at this year's meeting.
Diabetes Diagnosis and Management is presented by The Endocrine Society and its Hormone Health Network. This annual workshop focuses on current issues in clinical diabetes management and provides state-of-the art updates. The complete Diabetes Diagnosis and Management recording is free on endosessions.org. To hear more from ENDO 2013, visit endosessions.org
Program Highlights * William F. Young, MD, from the Mayo Clinic, Rochester, MN, Immediate Past-Presdient of The Endocrine Society provides an overview of this year's sessions * Sophie Jamal, MD, PhD, FRCPC from the University of Toronto reviews her research in osteoporosis and chronic kidney disease * Heather B. Patisaul, PhD, from North Carolina State University describes the endocrine disruptions on puberty when exposed to chemicals in the environment * Alex Stagnaro-Green, MD, MHPE, George Washington School of Medicine provides insights on new data in thryoid disease and pregnancy * Richard S. Legro, MD, FACOG, Penn State …
Guest: Paresh Dandona, MD, PhD
Host: Farhad Zangeneh, MD
Host Dr. Farhad Zangeneh welcomes Paresh Dandona MD, PhD, Professor and Chief of Endocrinology in the Department of Medicine at the University of Buffalo. His Specialty and Research Focus are in Endocrinology, Diabetes and Metabolism. He is also the Founder & Medical Director of the Diabetes-Endocrinology Center of Western New York. In this program, Dr. Dandona will be discussing insulin induced cardioprotection, inflammatory and oxidative stress in acute myocardial infarction. He will also review hyperglycemia and cardiotoxicity in acute myocardial infarction. Please take a listen!
Guest: Robert A. Rizza, MD
Host: Farhad Zangeneh, MD
What are the sources of glucose in the body? Is diabetes a pancreatic disease or a hepatic disease? What is the importance of glucose toxicity in Type 1 or Type 2 diabetes patients? To answer these questions and many more, join our host Dr. Farhad Zangenh in a discussion with Dr. Robert Rizza, an authority in the regulation of carbohydrate metabolism in humans, and the Executive Dean for Research at Mayo Clinic. Download the podcast and listen in!
Host: Farhad Zangeneh, MD
Guest: Paul Jellinger
In diabetes management, clinicians typically measure glycemic control with fasting plasma glucose (FPG) and premeal glucose measurements, and HbA1c. And, the goals for each of these measurements have been established based on the results of many clinical trials. However, the majority of patients with diabetes fail to achieve these glycemic goals. Elevated postprandial glucose (PPG) concentrations may contribute to suboptimal glycemic control. Host Dr Farhad Zangeneh is joined by Dr. Paul Jellinger who will address the issue of postprandial glucose and its complications.
Paul S. Jellinger, MD and Master of the American College of Endocrinology (MACE) serves as Professor of Medicine on the voluntary faculty at the University of Miami and served as Chief of the Section of Endocrinology at Memorial Regional Hospital in Hollywood, Florida. Dr. Jellinger served as president of the AACE, the ACE and the Florida Endocrine Society. Dr. Jellinger has been active on the AACE Board of Directors.
Guest: Robert Busch, MD
Host: Farhad Zangeneh, MD
Host Dr. Farhad Zenganah is joined by Dr. Robert Busch and they will be discussing current incretin treatment options and what is in the pipeline. They will discuss the differences between oral and injectables incretin treatment options and how clinicians can individualize treatment options for their patients, while determining the benefits and risks.
Robert Busch, MD, is a practicing endocrinologist and founding member of The Endocrine Group in Albany, New York. Dr. Busch is a member of the board of trustees at the Albany College of Pharmacy. He has enthusiastically enjoyed teaching medical students, pharmacists, physician assistants, nurse practitioners, and physicians for over 25 years.He is a principal investigator in numerous clinical trials.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Harold Bays, MD, FNLA
Host Dr. Alan Brown and guest, Dr. Harold Bays discuss the evolving treatments in lipid management and what we will be expecting in the future. They will address the role of niacin, the status of laropiprant, an overview of fish oils and omega-3 fatty acids and the novel approaches being used in today's research of lipid-altering drugs.
Harold E. Bays MD, FACP, FACE, FNLA is the Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC) in Louisville, KY. And, has served as an Investigator in over 400 Phase I - IV clinical trials for treatments for high cholesterol and other dyslipidemias, obesity, diabetes mellitus, hypertension, osteoporosis, and other metabolic and hormonal disorders. Dr. Bays has also served as Medical Director of L-MARC Research Center since 1989 - a clinical research facility originally established in 1989 - and President of L-MARC Research Center since its independent incorporation in 1998.
Guest: Eric Rackow, MD
Host: Steven Edelman, MD
The percentage of healthcare spending on chronic illnesses is increasing exponentially; critically for patients with diabetes. How can healthcare providers help their aging population to manage their diabetes and avoid costly hospital stays through home care management? Join host Dr. Steven Edelman and his guest, professor of medicine at the New York University School of Medicine, Dr. Eric Rackow, as they discuss new approaches for home care management strategies for patients living diabetes.
Guest: Simon Heller, MD
Host: Steven Edelman, MD
In 2004 the American Diabetes Association working group defined the threshold of hypoglycemia as 70 mg/dl. The clinical definition continues to attract controversy with a standard vs. dynamic solution. What are considerations that need to be made in terms of the clinical definition of hypoglycemia? Join host Dr. Steven Edelman and his guest, professor of clinical diabetes at the University of Sheffield, Dr. Simon Heller, as they discuss the challenge with the current threshold of hypoglycemia.
Guest: Eric Topol, MD
Host: Timothy Bailey, MD
The challenges of treating diabetes include long-term monitoring and management, lifestyle change and adherence to medication. How are digital technology and genomics shaping the management of diabetes? Join guest host Dr. Timothy Bailey and his guest Dr. Eric Topol, director of the Scripps Translational Science Institute, as they discuss how digital technologies can improve glucose monitoring and genomics is leading to individualized treatment. Dr. Topol, who does not have diabetes, describes his personal experience living with continuous glucose monitoring for one week.
Disclosures Dr. Eric Topol has disclosed that he has received grants for clinical research from sanofi-avenitis. Dr. Topol has also disclosed that he has served as an advisor or consultant to sanofi-aventis and Daiichi Sankyo.
Guest: Linda Raynes Mahony, MS, RD, CDE
Host: Steven Edelman, MD
Fifty percent of patients living with diabetes will require some sort of renal replacement therapy. What percent will go on to renal transplantation and what are the recommendations for the management of these patients? Join host Dr. Steven Edelman and his guest, transplant dietitian at the University of California, San Diego, Linda Raynes Mahony, as they discuss medications, nutrition and overall management of renal transplant patients.
Guest: Diana Zuckerman, PhD
Host: Maurice Pickard, MD
The lap-band device dramatically reduces the size of a patient's stomach, and as such, it can be effective for weight loss in very obese patients. It offers at least one major advantage over gastric bypass surgery, in that the lap-band can be removed. But can the lap-band procedure also be safe and effective for patients who are even slightly obese, or do the potential risks outweigh the benefits for these patients? Dr. Diana Zuckerman, president of the National Research Center for Women & Families and its cancer prevention and treatment fund in Washington, D.C., discusses the criteria for patients to receive lap-banding. What concerns surround the issue of lowering the body-mass index (or BMI) threshold for patients eligible for this procedure? What are the long-term risks of lap-bands? Dr. Maurice Pickard hosts.
Guest: R. Keith Campbell, BPharm, MBA
Host: Steven Edelman, MD
Changes in both care and treatment of diabetes reflect trends in healthcare that may need revision. How can healthcare professionals benefit from new pharmacotherapies for their patients living with diabetes? Join host Dr. Steven Edelman and his guest, professor of pharmacy, Keith Campbell, as they discuss trends in healthcare that may require revisions for the care of people living with diabetes.
Guest: Sally Hara, MS, RD, CDE, CSSD
Host: Janice Baker, MBA, RD, CDE, CNSC
Exercise is essential for controlling blood sugar levels in patients with diabetes but benefits also present a set of unique challenges to athletes. What are the concerns medical professionals should be aware of and monitor for their athletes living with diabetes? Join guest host Janice Baker and Sally Hara, certified specialist in sports dietetics, as they discuss prescribing exercise regimens for the diabetic athletes.
Host: Janice Baker, MBA, RD, CDE, CNSC
Guest: Monika Woolsey
There are many challenges in overall diabetes management relative to a patients' mindful integration of food and behavior. What do healthcare professionals need to know to help their patients with diabetes better manage diet, stress and physical activity? Join guest host Janice Baker, CDE, RD and her guest, president and founder of "After The Diet" network, Monika Woolsey, RD, as they discuss the biochemistry and appetite regulation of diabetes and diet.
Guest: William Polonsky, PhD, CDE
Host: Janice Baker, MBA, RD, CDE, CNSC
Stress is an integral element in the management of diabetes. What are key questions healthcare professionals can ask of their patients dealing with diabetes-related stress? Join guest host Janice Baker, CDE, RD and her guest, founder of the Behavioral Diabetes Institute, Dr. William Polonsky, as they discuss the basics of stress and diabetes and we can better help our patients living with diabetes.
Guest: John Buse, MD, PhD
Host: Steven Edelman, MD
The recent American Diabetes Association / European Association for the Study of Diabetes consensus panel produced their treatment algorithm to control glycaemia in type 2 diabetes. How can healthcare professionals treating patients with type 2 diabetes provide additional prandial intervention to reach A1c targets? Join host Dr. Steven Edelman and his guest, professor of medicine at the University of North Carolina School of Medicine, Dr. John Buse, as they discuss the results of the glargine-exenatide combination study and its implications for a preferred treatment algorithm.
Guest: Jay Skyler, MD
Host: Steven Edelman, MD
Can immune intervention stop the disease process of type 1 diabetes? Join host Dr. Steven Edelman and his guest, professor of medicine, pediatrics and psychology at the University of Miami, Dr. Jay Skyler, as they discuss the diagnosis, screening, testing and current immunotherapy research for the prevention and intervention of type 1 diabetes.
Guest: Christine Kessler
Host: Mimi Secor, DNP, FNP-BC, FAANP
What makes Americans fat? Diet isn't entirely to blame. Christine Kessler, who is a nurse practitioner in the department of endocrinology and metabolic medicine at a Washington, DC, teaching hospital, joins host Mimi Secor to discuss the many variables that are attributed to obesity in this country. They also look at what nurse practitioners can do to help their patients come up with strategies for living healthier lives.
Guest: Craig Wargon, DPM
Host: Steven Edelman, MD
Patients with diabetes commonly need treatment for peripheral neuropathy. What are common symptoms and what should a physician be looking for in each patient visit? Join host Dr. Steven Edelman and his guest, practicing physician in the division of podiatric surgery at Kaiser Permanente, Dr. Craig Wargon, as they discuss symptoms, treatment and the need to glycaemic control in patients with diabetes.
Guest: Gerald Reaven, MD
Host: Maurice Pickard, MD
Metabolic syndrome is generally considered to be a combination of conditions that increases a patient's risk of developing coronary artery disease. These conditions include elevated blood pressure, obesity, insulin resistance, elevated C-reactive proteins and high triglycerides or HDL cholesterol. If a patient has three or more of these conditions, he or she is classified as having metabolic syndrome. But what is the clinical applicability of this "syndrome," and should practicing physicians still be using the metabolic syndrome concept? Dr. Gerald Reaven, active emeritus professor of medicine at the Stanford University School of Medicine in Stanford, California, suggests that there are more reliable methods than the metabolic syndrome classification for determining a patient's risk of developing coronary artery disease. Dr. Maurice Pickard hosts.
Guest: Emmanuel Baetge, PhD
Host: Steven Edelman, MD
Current stem cell therapy research is leading the way into producing functional pancreatic, insulin-producing cells. How will this translate into clinical trials and human therapy for diabetes from a scale, delivery and efficacy position? Join host Dr. Steven Edelman and his guest Dr. Emmanuel Baetge, chief scientific officer of Viacyte, Inc., as they discuss the benefits of stem cell research therapy for diabetes.
Guest: Robert Cuddihy, MD
Host: Steven Edelman, MD
There have been impressive results with incretin-based therapy for patients with type 2 diabetes: improved A1C, beta-cell preservation and weight loss are some of the benefits. But do healthcare professionals need to temper their enthusiasm for this novel therapy? Join host Dr. Steven Edelman and his guest, medical director of the International Diabetes Center, Park Nicollet Health Services, Dr. Robert Cuddihy, as they discuss whether incretin-based therapy holds promise of a truly disease-modifying therapy.
Guest: David Kendall, MD
Host: Steven Edelman, MD
The assessment of intensive glycemic control in preventing cardiovascular disease is unclear. Discrepancies in recent clinical trials such as ACCORD, ADVANCE, PROactive and UKPDS 80 may reflect difference in study design and patients, versus glycemic control. How can using the Archimedes model illuminate this quandary? Join host Dr. Steven Edelman and his guest, chief scientific and medical officer of the American Diabetes Association, Dr. David Kendall, as they discuss the effect of glycemic control on macrovascular outcomes in patients with diabetes.
Guest: Barbara Rolls, PhD
Host: Steven Edelman, MD
Current studies are reflecting the relationship between dietary energy density and energy intake in the management of the obese and patients with diabetes. How can physicians learn to integrate diet strategies for weight management in their patients with diabetes? Join host Dr. Steven Edelman and his guest, professor of nutritional sciences at Penn State University, Dr. Barbara Rolls as they discuss the benefits of diets low in energy density and "volumetrics."
Host: Janice Baker, MBA, RD, CDE, CNSC
Guest: Lorena Drago, MS, RD, CDN, CDE
Whole grains have the potential to lower cholesterol as well as help manage blood glucose levels. What is the advantage of a whole grain diet in the management of diabetes? Join guest host registered dietitian Janice Baker and her guest, certified diabetes educator Lorena Drago, as they discuss the myths and facts of a whole grain diet in the management of diabetes.
Host: Larry Kaskel, MD
Guest: Elizabeth Tieman, MD
Work-life balance: how many of us can say we have it, let alone come close to having it? Board-certified radiologist Dr. Betsy Tieman is one healthcare professional who can say she achieved work-life balance by leaving private practice where she was working 14 hours a day to take advantage of locum tenens work, which also enabled her to train and compete in triathlons.